Nested case-control study of the emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae. 2013

Masayuki Nigo, and Catalina Salinas Cevallos, and Krystina Woods, and Vicente Maco Flores, and Gweneth Francis, and David C Perlman, and Manuel Revuelta, and Donna Mildvan, and Mary Waldron, and Tessa Gomez, and Sanjana Koshy, and Tomasz Jodlowski, and William Riley, and Jörg J Ruhe
Department of Medicine.

We performed a nested case-control study (ratio of 1:4) on the emergence of tigecycline-resistant multidrug-resistant Klebsiella pneumoniae (TR-MDRKP) isolates among patients who initially presented with a tigecycline-susceptible MDRKP isolate. Out of 260 patients, 24 (9%) had a subsequent clinical culture positive for a TR-MDRKP isolate within the 90-day follow-up period. On logistic regression analyses, receipt of tigecycline (adjusted odds ratio [OR], 5.06; 95% confidence interval [CI], 1.80 to 14.23; P = 0.002) was the only independent predictor of subsequent isolation of a TR strain.

UI MeSH Term Description Entries
D007710 Klebsiella Infections Infections with bacteria of the genus KLEBSIELLA. Infections, Klebsiella,Infection, Klebsiella,Klebsiella Infection
D007711 Klebsiella pneumoniae Gram-negative, non-motile, capsulated, gas-producing rods found widely in nature and associated with urinary and respiratory infections in humans. Bacillus pneumoniae,Bacterium pneumoniae crouposae,Hyalococcus pneumoniae,Klebsiella pneumoniae aerogenes,Klebsiella rhinoscleromatis
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008911 Minocycline A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections. Akamin,Akne-Puren,Aknemin,Aknin-Mino,Aknosan,Apo-Minocycline,Arestin,Blemix,Cyclomin,Cyclops,Dentomycin,Dynacin,Icht-Oral,Klinomycin,Lederderm,Mestacine,Minakne,Mino-Wolff,Minocin,Minocin MR,Minoclir,Minocycline Hydrochloride,Minocycline Monohydrochloride,Minocycline, (4R-(4 alpha,4a beta,5a beta,12a beta))-Isomer,Minolis,Minomycin,Minoplus,Minotab,Minox 50,Mynocine,Akne Puren,Aknin Mino,Apo Minocycline,Hydrochloride, Minocycline,Icht Oral,Mino Wolff,Monohydrochloride, Minocycline
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078304 Tigecycline A tetracycline derivative that acts as a protein synthesis inhibitor. It is used as an antibacterial agent for the systemic treatment of complicated skin and intra-abdominal infections. It is also used for the treatment of community-acquired pneumonia. 9-(tert-Butylglycylamido)minocycline,GAR 936,GAR-936,TBG-MINO,Tygacil,GAR936

Related Publications

Masayuki Nigo, and Catalina Salinas Cevallos, and Krystina Woods, and Vicente Maco Flores, and Gweneth Francis, and David C Perlman, and Manuel Revuelta, and Donna Mildvan, and Mary Waldron, and Tessa Gomez, and Sanjana Koshy, and Tomasz Jodlowski, and William Riley, and Jörg J Ruhe
August 2012, Antimicrobial agents and chemotherapy,
Masayuki Nigo, and Catalina Salinas Cevallos, and Krystina Woods, and Vicente Maco Flores, and Gweneth Francis, and David C Perlman, and Manuel Revuelta, and Donna Mildvan, and Mary Waldron, and Tessa Gomez, and Sanjana Koshy, and Tomasz Jodlowski, and William Riley, and Jörg J Ruhe
June 2022, Journal of global antimicrobial resistance,
Masayuki Nigo, and Catalina Salinas Cevallos, and Krystina Woods, and Vicente Maco Flores, and Gweneth Francis, and David C Perlman, and Manuel Revuelta, and Donna Mildvan, and Mary Waldron, and Tessa Gomez, and Sanjana Koshy, and Tomasz Jodlowski, and William Riley, and Jörg J Ruhe
January 2021, Frontiers in microbiology,
Masayuki Nigo, and Catalina Salinas Cevallos, and Krystina Woods, and Vicente Maco Flores, and Gweneth Francis, and David C Perlman, and Manuel Revuelta, and Donna Mildvan, and Mary Waldron, and Tessa Gomez, and Sanjana Koshy, and Tomasz Jodlowski, and William Riley, and Jörg J Ruhe
November 2021, Journal of infection in developing countries,
Masayuki Nigo, and Catalina Salinas Cevallos, and Krystina Woods, and Vicente Maco Flores, and Gweneth Francis, and David C Perlman, and Manuel Revuelta, and Donna Mildvan, and Mary Waldron, and Tessa Gomez, and Sanjana Koshy, and Tomasz Jodlowski, and William Riley, and Jörg J Ruhe
June 2023, The Lancet. Microbe,
Masayuki Nigo, and Catalina Salinas Cevallos, and Krystina Woods, and Vicente Maco Flores, and Gweneth Francis, and David C Perlman, and Manuel Revuelta, and Donna Mildvan, and Mary Waldron, and Tessa Gomez, and Sanjana Koshy, and Tomasz Jodlowski, and William Riley, and Jörg J Ruhe
March 2021, Journal of medical microbiology,
Masayuki Nigo, and Catalina Salinas Cevallos, and Krystina Woods, and Vicente Maco Flores, and Gweneth Francis, and David C Perlman, and Manuel Revuelta, and Donna Mildvan, and Mary Waldron, and Tessa Gomez, and Sanjana Koshy, and Tomasz Jodlowski, and William Riley, and Jörg J Ruhe
October 2023, ACS infectious diseases,
Masayuki Nigo, and Catalina Salinas Cevallos, and Krystina Woods, and Vicente Maco Flores, and Gweneth Francis, and David C Perlman, and Manuel Revuelta, and Donna Mildvan, and Mary Waldron, and Tessa Gomez, and Sanjana Koshy, and Tomasz Jodlowski, and William Riley, and Jörg J Ruhe
January 2021, Frontiers in microbiology,
Masayuki Nigo, and Catalina Salinas Cevallos, and Krystina Woods, and Vicente Maco Flores, and Gweneth Francis, and David C Perlman, and Manuel Revuelta, and Donna Mildvan, and Mary Waldron, and Tessa Gomez, and Sanjana Koshy, and Tomasz Jodlowski, and William Riley, and Jörg J Ruhe
January 2021, Frontiers in cellular and infection microbiology,
Masayuki Nigo, and Catalina Salinas Cevallos, and Krystina Woods, and Vicente Maco Flores, and Gweneth Francis, and David C Perlman, and Manuel Revuelta, and Donna Mildvan, and Mary Waldron, and Tessa Gomez, and Sanjana Koshy, and Tomasz Jodlowski, and William Riley, and Jörg J Ruhe
January 2020, Frontiers in cellular and infection microbiology,
Copied contents to your clipboard!